Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1991017770) SYNERGISTIC TUMOR THERAPY WITH COMBINATIONS OF BIOLOGICALLY ACTIVE ANTI-TUMOR ANTIBODIES AND CHEMOTHERAPY
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1991/017770 International Application No.: PCT/US1991/003483
Publication Date: 28.11.1991 International Filing Date: 17.05.1991
Chapter 2 Demand Filed: 20.12.1991
IPC:
A61K 38/00 (2006.01) ,A61K 39/395 (2006.01) ,A61K 45/06 (2006.01) ,A61K 47/48 (2006.01) ,C07K 16/30 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
48
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants:
BRISTOL-MYERS SQUIBB COMPANY [US/US]; 345 Park Avenue New York, NY 10154, US
Inventors:
HELLSTROM, Karl-Erik; US
HELLSTROM, Ingegerd; US
GOODMAN, Gary, E.; US
Agent:
SORRENTINO, Joseph, M.; Bristol-Myers Squibb Company 3005 First Avenue Seattle, WA 98121 , US
Priority Data:
527,22722.05.1990US
Title (EN) SYNERGISTIC TUMOR THERAPY WITH COMBINATIONS OF BIOLOGICALLY ACTIVE ANTI-TUMOR ANTIBODIES AND CHEMOTHERAPY
(FR) THERAPIE ANTICANCEREUSE SYNERGIQUE COMBINANT DES ANTICORPS ANTITUMORAUX BIOLOGIQUEMENT ACTIFS ET LA CHIMIOTHERAPIE
Abstract:
(EN) The present invention relates to the use of combinations of antibody therapy and chemotherapy in the treatment of malignant disease. It is based in part, on observation so if the surprising effectiveness of combination therapy; several patients who had received the anti-tumor antibody L6 or MG21 achieved complete remission in response to subsequent chemotherapy, although the same patients had not responded to similar chemotherapy regimens prior to receiving L6 or MG21 antibody treatment. Embodiments of the invention, antiglycolipid antibodies such as, preferably, L6 monoclonal antibody or MG21 monoclonal antibody, are administered to patients who are subsequently treated with standard chemotherapy regimens. In preferred embodiments of the invention, chemotherapy is administered within several months of antibody treatment. It is suggested that the effectiveness of combination therapy may be attributable to antibodies at the tumor site which render the malignant cells more susceptible to the toxic effects of chemotherapeutic agents.
(FR) L'invention se rapporte à l'utilisation d'une thérapie combinant la thérapie anticorpale et la chimiothérapie dans le traitement des affections malignes. L'invention se base en partie sur l'observation de l'efficacité surprenante de telles thérapies combinées, à savoir que plusieurs patients ayant reçu l'anticorps antitumoral L6 ou MG21 ont connu une rémission complète en réaction à un traitement chimiothérapeutique ultérieur, tandis que les mêmes patients n'avaient réagi à des régimes de chimiothérapie similaires avant de recevoir un traitement par l'anticorps L6 ou MG21. Dans des modes de réalisation de la présente invention, des anticorps antiglycolipides, tels que de préférence l'anticorps monoclonal L6 ou l'anticorps monoclonal MG21, sont administrés à des patients qui sont ensuite traités par des régimes de chimiothérapie standard. Dans les modes de réalisation préférés de la présente invention, la chimiothérapie est administrée après plusieurs mois de traitement anticorpal. On suppose que l'efficacité de cette thérapie combinée peut être attribuée à des anticorps agissant sur le site de la tumeur qui rendent les cellules malignes plus sensibles aux effets toxiques des agents chimiothérapeutiques.
Designated States: CA, HU, JP, KR
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
ZA1991/03879EP0575321JPH05508630CA2083391KR1019930700154